Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors

Aardvark Therapeutics (AARD) is facing a securities class action (26-cv-04643) alleging its IPO/Offering Documents and subsequent disclosures were misleading, particularly around ARD-101 safety and prospects. The complaint ties back to ARD-101 setbacks: the Phase 3 HERO trial was voluntarily paused on Feb. 27, 2026, after which the stock fell 56.2% (from $12.49 to $5.47), and a full FDA clinical hold was issued on May 14, 2026, driving another 32.1% drop (to $4.57). The filing adds litigation and credibility risk, with shares still trading below the $16.00 IPO price.

Analysis

This is less a litigation catalyst than a capital-structure reset. The core damage is not the lawsuit itself; it is that a clinical hold converts AARD from a binary-data story into a financing and survivability story, which tends to compress the multiple well before any legal outcome is known. In small-cap biotech, once regulators question a safety signal, the market typically assumes higher trial costs, slower timelines, and a lower probability of eventual approval, all of which raise dilution risk even if the company can still litigate the disclosure claims.

The second-order loser is any comparable microcap metabolic/PWS platform still marketing “differentiated” gut-restricted oral mechanisms; investors will now demand cleaner safety packages and larger buffers before underwriting early efficacy. That should also pull capital toward better-capitalized obesity/metabolic names and away from speculative single-asset programs, especially those with short cash runways or no partnering optionality. The immediate bounce risk is only on headline settlement chatter, but the real catalyst path is months long: hold updates, cash burn, and whether management can secure a partner or raise without punitive dilution.

The contrarian point is that the class action is probably not the tradeable event; the market already voted on the safety signal with the stock collapse. If the company’s runway is still adequate and the FDA hold is narrower than feared, the equity could be less impaired than the current narrative implies, but that requires hard data not legal process. What would falsify the bearish view is a partial hold lift, a restart of dosing, or non-dilutive financing that pushes the next equity raise well out; absent that, the path of least resistance remains lower.

Key Decisions for Investors

• Avoid initiating fresh long exposure in AARD for 1-3 months; the main risk is not damages but forced dilution if cash burn collides with the clinical hold.
• If borrow and liquidity are usable, maintain only a tactical short AARD into any litigation-driven relief rally; target is a retrace of 15-25% on headline optimism, with a hard stop if the FDA grants a partial hold lift.
• Preferred relative-value expression: long XBI / short AARD as an idiosyncratic hold-risk hedge over 1-2 quarters; the idea works only if sector beta recovers while AARD remains regulator-bound.
• Set an alert for financing disclosures and cash runway commentary at the next 10-Q/8-K; if runway is <12 months, expect another leg down from dilution risk rather than lawsuit headlines.
• Watch for FDA hold resolution or protocol redesign over the next 1-3 months; that is the only credible upside catalyst that can re-rate the name meaningfully.